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Abstract
Aberrations in gene expression are a hallmark of cancer cells. Differential tumor-specific transcript levels of single genes or
whole sets of genes may be critical for the neoplastic phenotype and important for therapeutic considerations or useful as
biomarkers. As an approach to filter out such relevant expression differences from the plethora of changes noted in global
expression profiling studies, we searched for changes of gene expression levels that are conserved. Transcriptomes from
massive parallel sequencing of different types of melanoma from medaka were generated and compared to microarray
datasets from zebrafish and human melanoma. This revealed molecular conservation at various levels between fish models
and human tumors providing a useful strategy for identifying expression signatures strongly associated with disease
phenotypes and uncovering new melanoma molecules.
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Introduction
Melanoma is one of the most aggressive forms of cancer with still
rapidly increasing incidence in the western world [1] (http://seer.
cancer.gov/csr/1975_2008/browse_csr.php?section= 16&page=
sect_16_table.05.html). Treatment opportunities arise from a large
portfolio of candidate drugs some of which have made it to clinical
studies; however, with differing and often unpredictable outcomes.
Thus the need for a better molecular understanding of melano-
magenesis and preclinical studies in-vitro and in animal models is
undisputed [2].
Melanoma is a paradigm for the complexity of cancer.
Melanomas arise from pigment cells of the skin, from extra-
cutaneous sites and from the uvea of the eye. A certain fraction of
cutaneous melanomas form on the basis of nevi, which then
represent a precursor lesion. Others are supposed to originate
from single pigment cells of the skin. The clinical heterogeneity of
the disease is astonishingly high, ranging from spontaneous total
remission to extremely fast, fatal progression. Although gene
expression signatures of melanomas have been reported
[3,4,5,6,7], only few clues were obtained for molecular subtypes
that could be of clinical relevance. Obvious differences were more
correlated to anatomical sites, treatment history of patients, and
progression stage. A further complication widely discussed to
camouflage a clear diagnostic gene expression signature, are
individual genetic differences and recurrent changes that reflect
epiphenomena of the transformed phenotype and the pathological
physiology of the melanoma cells. In general, and especially in the
melanoma field, high throughput transcriptome studies have so far
not revealed the expected consensus alterations that would help to
ultimately understand melanoma biology and pathology (for
discussion see [8]. To pinpoint relevant expression patterns
common to all tumor subtypes important information can be
obtained from a cross-species comparative approach with mela-
noma animal models. Changes in gene expression that are
conserved over large evolutionary distances have a high probabil-
ity of reflecting common molecular mechanisms critical for the
development of the same disease in different organisms [9,10,11].
We have developed a new model for pigment cell cancer in
small laboratory fish [12] that cannot only be used for functional
analyses but is also suited for high throughput studies. In this
model the melanoma oncogene xmrk from Xiphophorus [13] is
expressed under control of the mitf promoter in transgenic medaka
fish. Medaka is a complementary model to zebrafish with similar
characteristics and advantages for biomedical research [11].
Depending on a homogeneous, strain-specific genetic background,
carriers of the transgene develop pigment cell tumors of different
characteristics. These include uveal melanoma, exophytic epider-
mal pigment cell tumors of low malignancy, and invasive,
metastatic melanoma. We used the new massively parallel
sequencing technologies to establish transcriptomes of the different
pigment cell tumor types and a precursor lesion and to provide a
basis for comparison with human melanoma. We find in this
animal model a high number of tumor-specific differentially
regulated genes that have been assigned a diagnostic or functional
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role in human melanoma and we could identify sets of genes
whose dysregulation is conserved in melanoma from fish to man.
Results
For the RNA sequencing analyses three different tumor samples
were used. These included a heavily melanized uveal melanoma
(UM) that had already invaded the skull towards the central
nervous system, a nodular, apparently exclusively exophytically
growing xanthoerythrophoroma (XE) and an extracutaneous
melanoma (MM), which was a large jet black tumor mass in the
abdomen with massive invasion into the body musculature and
metastasis to inner organs including the spinal cord. Heavily
hyperpigmented skin (HP), a massive overproduction of pigment
cells that are different in shape from the normal pigment cells that
make up the basic pigmentation of the fish skin, but do not show
any signs of three-dimensional growth or invasion, was used for
comparison. Hyperpigmentation areas develop in fish only after
initial activation of an oncogene. They have been called F-nevi
and are regarded as the fish counterpart of human nevi [14].
At first the RNA-seq transcriptomes from the single tumors
were analyzed. Of the 24662 ENSEMBL medaka transcripts
between 9327 and 10376 transcripts were not expressed in the four
transcriptomes. Comparing the invasive MM with the exophytic
XE-tumor revealed 1442 transcripts that were only found in XE,
while 1789 were detected only in MM. 238 transcripts were at
least 10 fold (up to 42 fold) higher in XE than in MM, while 176
showed at least 10 fold (up to 72 fold) higher expression in MM
than in XE (Table S4).
From all annotated medaka transcripts 18415 had been
assigned a gene name. Only those (plus a few that we annotated
ourselves) were considered further. Expression of several genes
correlated with the different sublineages of pigment cells. As a
specific feature of the fish model, pigment cell tumors can either be
derived from melanin synthesizing cells or from pigment cells,
which contain pteridins and carotinoids. Consequently, we found
high expression of melanin pathway genes in MM and UM. The
XE tumor and the hyperpigmented skin showed low expression of
these genes, but abundantly expressed e.g. the rate limiting key
enzyme of the pteridine pathway, guanylyl cyclohydrolase.
The fish pigment cell tumors showed for several established
melanoma markers expression profiles comparable to mammalian
melanoma, for instance high expression of MART1/MLANA
[15], and upregulation of N-cadherin with simultaneous down-
regulation of E-cadherin [16]. The candidate suppressor of
malignant melanoma AIM1 was downregulated as well [17].
Consistent with earlier findings in fish [12], mouse and human
melanoma [18,19] the pigment cell specific transcription factor
mitf, which has been assigned a key role in maintaining the
proliferative state of melanoma cells [20,21,22], was upregulated.
A number of regulators of cell proliferation were differentially
expressed. CyclinD1, which is overexpressed in several neoplasms
and amplified in subset of melanomas [23] was higher expressed in
the tumors. While expression levels of the retinoblastoma gene
RB1 were unchanged, a strong downregulation of all members of
the p53 tumor suppressor gene family was observed.
The inhibitor of apoptosis BCL2 was considerably upregulated,
accompanied by a slight downregulation of FAS and higher
expression of FAS apoptotic inhibitory molecules1 and 2.
Growth factors and growth factor receptor signaling are very
important for various aspects of the malignant phenotype of
melanoma [24]. Of the many changes that we observed only some
can be mentioned here, for instance a 5 to 10 fold upregulation of
KIT and more than 15 fold upregulation of one of the two ERBB3
paralogs in MM and UM paralleled by a strong decrease of
melanocortin receptor 1. From the SRC kinases only FYN was
higher expressed in the tumors compared to the benign precursor
lesion, consistent with its more prominent role in xmrk-driven
melanoma [25,26].
Members of the RAS and RAF families, in particular N-RAS
and B-RAF, have attracted a lot of attention because they were
found to be mutated in a majority of human melanoma [27] but
transcript levels are generally not changed (https://www.
oncomine.org). Accordingly, neither in the RNASeq transcrip-
tomes nor in a larger survey on single fish tumors, regulation of ras
or raf genes was seen (data not shown).
Reactive oxygen species (ROS) metabolism is an important
regulator of oncogene-induced senescence and could be instru-
mental in the switch of benign precursor lesions to malignant
tumors [28,29]. ROS detoxifying enzymes (e.g. catalase, peroxir-
edoxin 6, superoxide dismutase) were considerably upregulated in
all tumor types. This is in accordance with proteome data from
Xiphophorus, where an increase of peroxiredoxins and other ROS
metabolizing enzymes was observed during melanoma develop-
ment [30,31].
The myc genes are central players in the development of many
cancers, but little is known about their role in melanoma. We
found upregulation of c-myc, N-myc and of the c-MYC target and
cell cycle progression activating transcription factor FOXM1.
An important feature of melanoma progression is that the
switch from proliferative to invasive phenotype correlates with
changes in wnt/ß-catenin signaling. In the tumors all Wnt family
ligands were downregulated. In the m ore aggressive MM and UM
there was a concomitant strong upregulation of the Wnt signaling
antagonists dickkopf 3 and secreted frizzled-related protein (frzB), while in
the XE tumor only a slight upregulation of frzB was noted.
To validate the RNASeq data that were generated from one
tumor each quantitative RT-PCR of a larger series of single
tumors was performed and compared to expression in healthy
organs, including skin, and the precursor lesion. In most cases
expression differences seen in the transcriptomes were also
obtained for a larger number of individual tumors. Of 22
arbitrarily selected genes, 14 showed the expression profile
predicted from RNA-seq, 6 were in the range of the transcriptome
data with single tumors of the whole set where expression was not
in line with the RNA-Seq, while in two cases the transcriptome
data were not confirmed. Generally, genes were expressed in each
tumor type with some variation over all samples resulting in a
continuum of expression levels (Figure 1). For genes, which in fish
due to the teleost-specific whole genome duplication are present in
two isoforms, we frequently noted a tumor subtype specific
expression (for example N-cadherin; Figure 1b, c).
An important feature of RNAseq transcriptome data is that they
provide information on alternatively spliced mRNAs. Of all genes
(n = 3151) that are annotated with different mRNA isoforms 614
were not expressed. 1776 genes were expressed as a single
transcript. 196 showed differential regulation and 565 displayed
regulation in the same direction. Of note, one of the three isoforms
of mitfa was highly upregulated in XE and MM, while a different
transcript was upregulated in UM (Table S3).
The above-indicated changes were all detected by screening the
RNAseq dataset for known players of tumor development. To
obtain information on a more systemic level we attempted to make
use of algorithms for the analysis of microarray data. Plotting the
average signal intensity of all groups versus fold change between
mean tumor log2 values and log2 of hyperpigmented skin for each
gene, 85% of the genes display a less than 4-fold regulation with an
average log ratio of zero indicating that there is no bias to either
Fish and Human Melanoma Transcriptome Comparison
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up or down regulation. Given a threshold for regulation of logFC
.2, p-value ,0.05 and provided that a gene is expressed (base
mean .10) in at least one group, in a comparison of the tumors to
each other or to hyperpigmented skin we found 640 genes to be
commonly regulated. However, differential expression could be
easily extracted on the single gene levels for the apparent outliers
of the MA-plot (Figure S1). For instance (Figure S2), tyrp1 is highly
up regulated in MM and UM. GCH1 is absent from UM, but high
in the three other samples. CYTL1 is highly expressed in HP,
though almost not expressed in all three tumor types. Conversely,
MLANA is very high in all tumors but absent in the premalignant
HP.
Using the functional annotation tool of the DAVID bioinfor-
matics resource revealed significant regulatory changes of certain
pathways. Each tumor was characterized by a unique set of
regulated genes but there were also common regulatory changes
when all three tumors where compared to HP (Table S2). Not
unexpectedly, coordinated regulation of genes from major
metabolic pathways (glycolysis, pentosesphosphate pathway, me-
tabolism of aminoacids and nucleotides), cell cycle control and
MAP kinase pathway within samples but different for each tumor
type became apparent (Figure 2). UM showed a more pronounced
upregulation of the protein translation machinery than MM and
XE. Consistently in all tumors there was downregulation of genes
involved in extracellular matrix (ECM) – receptor interactions, cell
adhesion molecules and cellular junctions (Figure 3, Figure S5).
Downregulation of cell adhesion molecules was up to 10 fold
stronger in invasive tumors than in non-invasive. In all affected
Figure 1. Quantitative real-time RT-PCR expression analyses of single MM, XE and UM tumors and hyperpigmented skin. 1a: sox10b
expression; 1b: N-cadherin expression (variant 1), 1c: N-cadherin expression (variant 2), 1d: dkk3 expression, 1e: frizzledB expression. 1f: slc45A2
expression, notably the three most highly expressing XE tumors (to the right) had some black pigmented areas. ef1-alpha served as reference. For
comparison, gene expression in normal tissue is shown. Groups showing significant differences in their expression are marked with *. Kruskal-Wallis
p-value for frizzledB was 0.051 and therefore only slightly above significance level.
doi:10.1371/journal.pone.0037880.g001
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pathways, a remarkably high number of pathway components
were altered, e.g. of the 67 ECM-receptor interactions listed in the
KEGG pathway 54 showed a regulatory change in at least one
component. 40 showed a downregulation in all tumor types. All
comparisons consistently revealed changes in regulators of the
calcium-signaling pathway.
Transformation of the RNA-Seq data also allowed comparison
of our data set to microarray expression analyses from zebrafish
melanoma [32]. Except for RAP2B all genes upregulated in
zebrafish were also upregulated in at least one tumor type in
medaka (Figure S3). In case of downregulated genes the majority
of the medaka genes (47 of 63, including different transcripts of the
same gene) behaved similarly as their orthologs in zebrafish
melanoma. Genes from the common cross-species expression
signature include pigment cell specific genes like tyrosinase but
also more widely expressed regulators of intracellular signaling
transduction, e.g. sprouty4.
Finally, we wanted to determine regulatory changes that are
conserved between pigment cell tumors in the fish model and
human melanoma. From the Talantov microarray datasets from
human samples 18 benign melanocytic skin nevi and 19 cutaneous
primary melanoma [33] were used, which appeared to be most
appropriate for comparison to our dataset, aligning the fish nevi
(HP) to human nevi and all fish tumors (XE,MM,UM, combined
into one group) to cutaneous primary melanoma. The analyses
revealed 49 genes that were commonly downregulated in fish and
human tumors while only MAP3K12 was found to be commonly
upregulated. Comparing the data from the medaka MM to the
human dataset revealed 65 genes to be commonly downregulated
and 20 upregulated genes. Assigning those genes to defined
pathways (Figure S4) uncovered genes involved in focal adhesion,
cell adhesion, ECM-receptor interaction, and markers of neuro-
ectodermal cells.
We also compared the fish tumor transcriptomes to the 105
genes that are derived from a large metaanalyses of microarray
data from human melanoma cells that has basically defined two
main motifs [34]. Of the 38 genes common with medaka from
motif 1, which is expressed by proliferative melanoma cells, 27
were upregulated more than 2 fold in all tumors. From motif 2,
which characterizes the invasive and prometastatic phenotype, 34
genes were shared with medaka, of which 27 were upregulated
more than 2 fold (Table S5):
To evaluate novel potential markers derived from our
comparative analyses, the entire set of melanoma cell lines from
the NCI60 panel was tested for expression of SLC45A2. This
revealed that in comparison to normal human epidermal
melanocytes (NHEM) eight of eleven melanoma cell lines showed
considerably enhanced expression levels of this gene (Figure 4).
SLC45A2 is a known component of the melanin pathway, but in
the tumors it was found to be upregulated even though they were
not melanized.
Discussion
RNA sequencing has so far not been used in fish models to
detect global expression changes that are helpful for better
understanding processes of tumor growth and progression. We
show that the enormous power of the new sequencing technology
can be combined with the already existing wealth of data from
chip-based microarray data. We did not search for possible
mutations, gene fusion transcripts and novel transcripts, because in
our melanoma model (like in other transgenic or natural genetic
models for cancer) the primary cause for tumor development is
known, here contributed by the specific overexpression of an
activated oncogene. In addition the short latency period of
melanoma development makes additional sporadic genomic
alterations and random mutations very unlikely to be critical for
tumor initiation. However, in other situations, where the causative
event of melanoma is unknown, RNA sequencing can be useful
also for detecting genomic changes relevant to tumor formation
([7]).
As a starting point for our analyses we used the transgenic
mitf::xmrk medaka melanoma model, which like transgenic mouse
models provides the advantage that the primary oncogenic trigger
for tumorigenesis is always the same. Due to the defined genetic
background melanoma development is stereotypic and the
research material should be comparable from individual to
individual. Importantly, our analysis shows that it is essential to
verify data by single gene/single tumor analysis, using quantitative
RT-PCR. Even in our melanoma model system with a more
uniform genetic background than the human population we found
an unexpected variation between samples. Certainly, melanoma
classification in fish is much less elaborate than in humans, but
special care was taken to collect tumors with comparable growth
characteristics, tumor size and location. This indicates that even
on a common genetic basis every single melanoma develops its
own molecular expression program, despite similar disease
phenotypes.
Small aquarium fish have become well accepted and useful
models for melanoma research [11] and have shown great promise
for drug discovery and detecting new melanoma genes [32,35].
Previous studies have used these systems as surrogates for
analyzing the action of mutated oncogenes in eliciting melanoma
formation and the interaction of known melanoma pathways with
the primary oncogene. One study compared the expression profile
of 16 candidate genes for cancer progression in a mutant HRAS
transgenic zebrafish melanoma model with data from human
melanoma, but found no consistent expression changes [36].
Another study reported microarray analyses of melanoma in
mutant NRAS;p532/2 zebrafish in comparison to normal skin
and human melanoma [37]. These authors noted ‘‘a high degree
of molecular similarity’’ of fish and human disease. However, only
up-regulated genes were found to be conserved between zebrafish
and human melanoma. As normal melanocytes are only a minor
constituent of normal skin (used as the reference tissue) downreg-
ulation of genes was rather difficult to deduce. We used
hyperpigmented skin for control where pigment cells make up a
major fraction and readily detected a number of conserved
downregulated genes.
For the BRAF;p532/2 zebrafish model a microarray gene
expression profile from melanoma was compared to embryonic
stages. Gene enrichment analyses uncovered a signature of 123
overlapping genes, which is similar to the signature of multipotent
neural crest progenitors [32]. Comparison to this signature
revealed a very good overlap with the gene expression profile of
the medaka pigment cell tumors.
Recently a critical evaluation of the existing human melanoma
microarray data was performed and uncovered strong discordance
due to inhomogeneity of patient cohorts and tumor samples. From
datasets showing the best match of material a meta-analysis was
done [38]. This revealed a list of only 17 dysregulated genes that
appear to be associated with melanoma progression. Interestingly,
this includes many genes that we found commonly regulated
between fish and human melanoma (e.g. BCL2, WNT family
members) or which became evident in the fish tumor comparisons,
e.g. components of the ECM, cell cycle regulators, PLP1, and
CLIC3.
Fish and Human Melanoma Transcriptome Comparison
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The profile of the fish pigment cell tumors showed also a large
overlap with the motifs of gene expressions that were established
from an extensive microarray analysis of many human melanoma
cell lines [34]. However, the tumor with the more invasive and
metastastic (MM) and the tumor with the more exophytic and less
invasive growing (XE) showed no clear separation into the
proliferative and invasive signatures. This may be explained by
the fact that our data are from whole tumor biopsies. Even the
exophytic tumor has areas of local invasion into deeper layers and
the underlying body musculature and the MM has large areas of
nodular growth. Thus, it can be expected that cells of both
characteristic will contribute to the RNA pool extracted from the
tumor.
The high expression of classical melanoma markers, upregula-
tion of N-cadherin, downregulation of E-cadherin, inhibitors of
cell cycle, growth promoting genes and inhibitors of apoptosis
demonstrates that the fish melanoma share many common
features on the gene expression levels equivalent to mammalian
pigment cell tumors, thus providing useful models. An interesting
aspect is the consistent downregulation of p53, p63 and p73. On
the one hand, this is also a strong contribution to inhibition of
apoptosis. On the other hand, the suppression of the p53/Cdkn2a
Figure 2. Heatplot (scaled) of differentially expressed genes from the MAP kinase pathway (2a), apoptosis (2b) and cell cycle
regulation (2c), displaying the quality of the read count distribution within the genes. Low read counts are colored in green, high read
counts are colored in red.
doi:10.1371/journal.pone.0037880.g002
Figure 3. Regulation of genes involved in ECM-receptor interaction (KEGG pathway: 04512). Genes displaying a logFC.2 and p-
value,0.05 in all three tumor types compared to hyperpigmented skin are marked green (down-regulated) squares.
doi:10.1371/journal.pone.0037880.g003
Fish and Human Melanoma Transcriptome Comparison
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arm of cell cycle control is know to be an important step in
melanomagenesis, although mutations in p53 gene family mem-
bers are generally more rare than in other tumors [39]. Repression
on the transcriptional level of those genes is another way to
produce a loss of function and could generate in a similar way an
uncontrolled proliferation response [40]. The observed upregula-
tion of cyclinD1 may lead in a similar way to the inactivation of
the RB1-pathway of cell cycle control. A cooperative action of p53
loss for initial melanoma formation in zebrafish Braf and Nras
models [14,37] and for melanoma progression in the medaka xmrk
melanoma model [12] has been documented.
The exact role of Wnt/ß-catenin signaling in melanoma is still
controversial, although evidence has been presented that activa-
tion of Wnt/ß-catenin results in decreased proliferation and leads
to upregulation of melanocyte differentiation genes [41]. The
consistent downregulation of Wnt signaling components and the
upregulation of Wnt antagonists in the more malignant and faster
growing tumors is in line with the predominant proliferative
nature of the tumors analyzed here. A deactivation of Wnt
signaling was also seen in human melanoma showing the
expression profile of highly aggressive and metastatic tumors [34].
Altogether our comparison of fish and human melanoma
defines a highly conserved expression program of pigment cell
tumors. It will be worthwhile to look in more detail into theses
genes for their usefulness as melanoma biomarkers and a
functional role for the malignant phenotype.
As a first example we found that the melanosome component
SLC45A2 was upregulated in MM and UM. This was confirmed
using the NCI60 melanoma cell lines. Interestingly this gene is also
highly expressed in the malignant sample fraction of other human
melanoma microarrays (https://www.oncomine.org). Hence it is a
promising candidate for a melanoma marker. SLC45A2 has earlier
been associated with melanoma only in the context of pigmentation,
where mutations in the gene confer higher melanoma risk [42,43].
Materials and Methods
RNA sequencing
Total RNA was isolated from a single uveal melanoma,
exophytic xanthoerythrophoroma and invasive, metastatic mela-
noma, while hyperpigmented skin was pooled from 5 siblings (for
detailed description of the genotypes and histopathology see [12]
and extracted with miRNAeasy kit (Qiagen). RNA quality was
checked using Agilent Bioanalyzer 2100 total RNA Nano series II
chip. Transcriptome libraries were prepared from total RNA using
Illumina mRNA-Seq Sample Preparation Kit. Libraries were
sequenced to a single read length of 51 nucleotides on an Illumina
GAIIx instrument according to the manufacturer’s recommenda-
tions. This protocol does not yield miRNA sequences and does not
allow fusion transcript identification. Image analysis and base-
calling were performed using the standard Illumina pipeline.
Resulting reads were trimmed of low quality nucleotides and
aligned against 24662 cDNA sequences predicted by ENSEMBL’s
O. latipes Genebuild (version 56, www.ensembl.org) using the CLC
bio Genomics Workbench version 3.6.5 (CLC bio, Aarhus,
Denmark). Alignment counts were normalized for transcript
length and total aligned reads (RPKM values) [44].
Bioinformatic analyses
A threshold level for RPKM values to reflect gene expression
above background was set to 2.
For easy and efficient comparison of transcriptomes we
employed CrossQuery [45]. It uses a MySQL database backend
with prejoined data-tables, which allows very fast query-returns.
The RNASeq datasets were logically associated, mathematically
filtered and sorted.
All data were analyzed using different R packages from the
Bioconductor project (www.bioconductor.org). RNA sequence
data were analyzed with ‘‘DESeq’’ [46], an R-package, which
Figure 4. Quantitative real-time RT-PCR analysis of SLC45A2 expression in LOX IMVI, M14, M19-Mel, Malme 3M, MDA-MB 435, RPMI
7951, SK Mel 2, SK Mel 5, SK Mel 28, UACC-62, and UACC-257 melanoma cells. NHEM cells served as expression control and were set as 1.
beta-actin was used as reference gene.
doi:10.1371/journal.pone.0037880.g004
Fish and Human Melanoma Transcriptome Comparison
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was written to test for differential expression in sequencing data.
Briefly, based on the aligned count data size factors were
estimated, which were used to calculate the effective library size.
Count variance was estimated across conditions, based on the
assumption that the majority of genes behave the same across
conditions and the variation calculated for one condition would
rather be too high than too low. This estimation of variance allows
using single data sets as well as data sets having replicates. To
detect differential expression, signal intensities, log-fold changes
(logFC) and p-values were calculated for each gene. For the
comparison of the fish RNA-Seq data genes were considered to be
differentially expressed, if logFC.2 in case of single sample
comparisons. For the comparison of all tumor types combined
versus hyperpigemented skin, to ensure good comparability
between tumor samples, in addition to a threshold for logFC the
p-value was required to be less than 0.05.
Human and zebrafish orthologues of medaka genes were found
by ENSEMBL IDs using ‘‘biomaRt’’. Functional interpretation and
clustering was done using the web-based annotation tool DAVID
(http://david.abcc.ncifcrf.gov/), applying 0.01 as EASE threshold.
For color display of pathways the KEGG Mapper (http://www.
genome.jp/kegg/tool/color_pathway.html) was used.
For comparison with human tumor samples we selected
Affymetrix microarray datasets from malignant melanoma and
benign nevi [33], (GEO acc.no: GSE3189). Raw data from .cel
files were quantile-quantile normalized [47], logFC and p-values
were calculated based on a modified t-test using the limma
package [48]. A gene was considered to be differentially regulated,
having a fold change .2 and a p-value,0.05.
To obtain a common dataset for human and fish, logFC
resulting from limma (human) and DESeq (medaka) were
combined on the basis of their gene symbols. Only genes common
to both datasets (n = 8289) were considered.
To obtain a set of alternatively spliced genes all gene IDs
corresponding to more than one transcript ID were filtered out.
Genes that were not expressed all tumor types (RPKM,2) were
excluded. To detect different regulation between transcripts for each
group and each gene (Gi) mean RPKM of all transcripts (Tij) were
calculated:
Gi~
1
ni
Xni
j~1
Tij
Correlations of each transcript to its corresponding gene mean values
were computed and the range of the correlation values within each
gene (RCgene) calculated. A gene was defined as alternatively spliced,
if RCgene.1.
To relate the fish expression profiles in relation to the 105 genes
defined for human melanoma cell phenotype-specific expression [34],
(http://www.dermatologie.usz.ch/Research/hoek/information/Seiten
/work_105.aspx) genes found to be differentially expressed in XE vs.
HP or MM vs. HP resulting from the DESeq package were
compared to those expressed by proliferative phenotype melanoma
cells (motif 1) and genes expressed by invasive phenotype melanoma
cells (motif 2).
Cell culture
Human melanoma cell lines from the NCI-60 panel (LOX IMVI,
M14, M19-Mel, Malme 3 M, MDA-MB 435, RPMI 7951, SK Mel
2, SK Mel 5, SK Mel 28,UACC-62, UACC-257) were cultivated in
DMEM supplemented with 10% FCS, penicillin (100 U/ml, Gibco),
and streptomycin (100 mg/ml, Gibco). The source of these human
melanoma cell lines is the DCTD Tumor Repository, National
Cancer Institute at Frederick, Frederick, Maryland. NHEM cells
were from Promocell and kept in Melanocyte Growth Medium.
Quantitative real-time PCR
RNA was extracted using TRIZOL (Invitrogen) or Total RNA
Isolation Reagent (ABgene). After DNase treatment, reverse
transcription was performed using Superscript II Reverse Tran-
scriptase (Invitrogen) or RevertAid First Strand Synthesis kit
(Fermentas) and random hexamer primers. cDNA from 15 ng of
total RNA for ef1 and 50 ng for all other transcripts was used for
realtime PCR (for primer sequences see Table S1) using SYBR
Green. Amplification was monitored with i-Cycler (Bio-Rad). All
results are averages of at least two independent reverse transcription
reactions and 2–5 PCR experiments from each such reaction. For
quantification data were analyzed by the DCt method [49], and
normalized to ef1amRNA for medaka and to beta-actin for human
samples. For spot check, not reversely transcribed RNA was used in
control PCR reaction. Data are presented as mean 6 standard
deviation. Changes in mRNA expression were tested using a
Kruskal-Wallis test and Mann-Whitney test, as post-hoc we used an
approach based upon the Tukey method as described [50].
Supporting Information
Figure S1 MA-plot of all melanoma samples compared
to hyperpigmented skin. Average expression of all groups is
plotted against the x-axis; average change of expression (log fold
change) is plotted against the y-axis. Red spots indicating genes
that have a p-value,0.01 and differential expression .4-fold up,
green spots indicating genes that have a p-value,0.01 and
differential expression .4-fold down in melanoma, grey spots
indicate genes that were defined as not expressed. 12 genes
showing the highest up-/down-regulation are annotated. Numbers
represent the end digits of the respective Ensembl transcript ID.
(PDF)
Figure S2 Log2 RPKM values of single differentially
regulated genes in the tumors (XE, MM, UM) and
hyperpigmented skin (HP). TYRP1 (2of2), tyrosinase related
protein 1, isoform 2; GCH1, guanylylcyclohydrolase 1; CYTL1,
cytokine-like 1, isoform 2; MLANA, melan-A.
(TIF)
Figure S3 Heatplot (scaled) of genes common in zebra-
fish and medaka, displaying the quality of the log2 read
count distribution within the genes. Low read counts are
colored in green, high read counts are colored in red. 3a: Genes
down-regulated in zebrafish, 3b: Genes up-regulated in zebrafish.
(TIF)
Figure S4 Affected pathways based on genes commonly
upregulated or downregulated more than 2-fold in
human cutaneous primary melanoma compared to
melanocytic skin nevi and fish tumors (XE, UM and
MM) compared to fish nevi (HP). Red bars show the number
of observed genes up-regulated or down-regulated in the dataset,
blue bars show the statistically expected number of genes, given
the result to be random.
(PDF)
Figure S5 Gene Ontology analysis of functional gene
groups commonly regulated in medaka tumors versus
HP. The analysis was performed using the Gene Set Analysis
Toolkit V2 (http://bioinfo.vanderbilt.edu/webgestalt/).
(GIF)
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Table S1 Primers used for quantitative real-time PCR
analysis.
(DOC)
Table S2 List of genes with a more than 4-fold
regulation in all tumors compared to the benign
precursor lesion.
(XLS)
Table S3 List of differentially spliced and differentially
expressed genes.
(XLS)
Table S4 Number of genes with RPKM.2 showing an at
least 2-fold up or down regulation in different tumor
types compared to hyperpigmented skin.
(DOC)
Table S5 Genes common in medaka tumor transcrip-
tomes and the Hoek human melanoma gene expression
signature. Columns 5 to 8 indicate in which datasets a gene is
commonly regulated (1) or not (0).
(XLS)
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